Article
"The emerging role of capivasertib in breast cancer".
Breast (Edinburgh, Scotland) - 1 Jun 2022
Andrikopoulou Angeliki, Chatzinikolaou Spyridoula, Panourgias Evangelia, Kaparelou Maria, Liontos Michalis, Dimopoulos Meletios-Athanasios, Zagouri Flora
Abstract excerpt
Over 50% of breast tumors harbor alterations in one or more genes of the phosphatidylinositol 3-kinase (PI3K) pathway including PIK3CA mutations (31%), PTEN loss (34%), PTEN mutations (5%) and AKT1 mutations (3%). While PI3K and mTOR inhibitors are already approved in advanced breast cancer, AKT inhibitors have been recently developed as a new therapeutic approach. Capivasertib (AZD5363) is a novel, selective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.